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Abstract
Objective. To determine whether a proliferation-inducing ligand (APRIL) has a role in the survival of
plasma cells infiltrating salivary glands from SS patients.
Methods. We performed immunological staining for APRIL in minor salivary glands from SS with a pair of
antibodies specifically recognizing APRIL-producing cells and secreted APRIL.
Results. Despite high leucocyte infiltration, APRIL-producing cells, identified as neutrophils, were rare in
SS salivary glands. Keratinocytes from the adjacent oral epithelium also produced APRIL, but we never
detected significant levels of secreted APRIL in SS salivary glands. We obtained similar results with B-cell
lymphomas associated with SS. In fact, there was no significant difference in APRIL production and the
level of secreted APRIL in these pathological samples compared with normal corresponding tissues.
Conclusion. The combined observation that APRIL production is not up-regulated in lesions from SS patients,
and that secreted APRIL is not retained in these lesions, indicates that plasma cells frequently present in SS
lesions may not rely on APRIL for survival, as they do in other rheumatic diseases.
Key words: Sjo¨gren’s syndrome, Inflammation, TNF, A proliferation-inducing ligand, Plasma cells.
Introduction
A proliferation-inducing ligand (APRIL, TNFSF13) is one of
the last members cloned from the TNF superfamily [1, 2].
APRIL modulates late steps of humoral immune re-
sponses by inducing immunoglobulin (Ig) switch [36],
and transmitting a survival signal into plasmablast/
plasma cells (PCs) [79]. Owing to this role, APRIL may
be implicated in autoimmune diseases with a humoral
component, such as the rheumatic diseases, RA, SLE
and SS [10]. In terms of expression, APRIL is up-regulated
in patients’ sera suffering from RA, SLE and SS [11].
In these diseases, APRIL may have a local role for PC
infiltrating lesions. Consistent with this, cells from the
myeloid lineage, including dendritic cells [11], macro-
phages and neutrophils [12], produce APRIL in synovium
from RA, confirming the APRIL up-regulation detected in
the SFs of patients [11]. For SLE, one report indicated that
PCs infiltrating kidneys from patients produce APRIL ab-
errantly [13]. These prompted the test of APRIL, and the
closely related B-cell activation factor from the TNF family
(BAFF, TNFSF13B) [14], antagonism in RA and SLE.
Recent Phase Ib reports indicated a promising reduction
in B cell numbers and Ig levels in both RA and SLE [15, 16].
APRIL expression in SS lesions has still not been studied.
Here, we studied APRIL expression in SS minor salivary
glands, and compared it with normal tissues.
Materials and methods
Patients
Lip biopsies performed for routine diagnosis were obtained
from 14 patients (11 women and 3 men) with a mean
age of 53 years (range 2582 years), fulfilling at least
four of the six European Community Criteria defining SS.
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These criteria include ocular symptoms, oral symptoms,
evidence of KCS, focal lymphocytic sialadenitis of minor
salivary glands, instrumental evidence of salivary gland
involvement and presence of autoantibodies to Ro/SSA
and/or to La/SSB [17]. Disease duration ranged from 0 to
4 years. Eight and four patients had circulating anti-SSA/
SSB Igs and hyper IgG, respectively. At the time of the
biopsy, patients had a focus score ranging from 2 to 6,
and were not undergoing any immunomodulatory treat-
ment. Four patients with a mean age of 60 years (range
4769 years) affected by secondary SS subsequent to
RA (n= 4) were also studied. Five patients with an occular
adnexal marginal zone B-cell lymphomas associated with
SS were also analysed. Normal salivary gland specimens
were obtained from individuals undergoing surgery for
benign lip lesions. All experiments were performed in
agreement with local ethics committees and patients’ in-
formed consent. The study was approved by the Geneva
Hospital Ethical Committee.
Immunohistochemistry
Immunohistochemistry (IHC) analyses were performed on
formalin-fixed paraffin-embedded tissues. Tissue reactiv-
ity for Stalk-1 and Aprily-8 antibodies was performed
with an antigen-retrieval step consisting of a microwave
treatment in 0.01 M citrate buffer of pH 6, as previously
described [18]. The anti-CD138 [gamma immunoglobulin
1 (IgG1), clone MI15] and anti-elastase (IgG1, clone NP57)
were from Dako-Cytomation (Glostrup, Denmark).
Peroxydase-conjugated secondary reagents have all
been described previously [18]. For multi-colour IF,
phycoerythrin-conjugated anti-mouse IgG1 goat serum
(Jackson ImmunoResearch Laboratories Inc., West
Grove, PA, USA) and alexa 488-conjugated anti-rabbit Ig
goat serum (Molecular Probes, Leiden, The Netherlands)
were used. 40,60-diamidino-2-phenylindole staining was
included in the merged images. Images were visualized
under light or fluorescent microscopy with Axiophot 1
(Carl Zeiss AG, Berlin, Germany), captured with an axio-
cam (Carl Zeiss AG) colour Charge-Coupled device
camera and treated on a Pentium III computer with
axioVision software (Carl Zeiss AG). Stalk-1-stained cells
and CD138+ PCs were numerated as previously described
[12] for a 4 mm2 section. Statistical analyses were per-
formed with a MannWhitney test. Quantification of the
Stalk-1 signal in epithelium was performed as previously
described in tonsils [9].
Results
APRIL expression in minor salivary glands from
patients with SS
We first assessed, by IHC, the presence of APRIL-
producing cells and secreted APRIL in salivary glands
from patients with SS. Cells producing APRIL, detected
by the Stalk-1 antibody, were rare, despite high infiltration
of leucocytes (Fig. 1A), and there was no staining with
Aprily-8, the antibody detecting secreted APRIL. Few of
the cells producing APRIL in the parenchyma lesion had a
segmented nucleus, and we identified them as elastase-
expressing neutrophils in two-colour IF staining (Fig. 1B).
There was no CD68+ macrophage that produced APRIL in
these SS lesions. Keratinocytes from the adjacent oral
epithelium were the main producers of APRIL (Fig. 1C).
APRIL-producing cells were located in the upper layers
of this epithelium, similar to the epithelium from tonsil
[9]. Epithelial cells secreted all the APRIL they produced,
since they were not stained with Aprily-8, consistent with
the efficient APRIL secretion observed in previously stu-
died tissues, including tonsil, small intestine and diverse
tumour lesions [19]. The interstitial tissue around salivary
glands did not retain APRIL secreted by the epithelium.
The latter observation is consistent with the known ab-
sence of communication between these two tissues. We
previously reported APRIL up-regulation in some B-cell
lymphomas, both at the level of APRIL production and
accumulation of secreted APRIL on tumour cells [18, 20,
21]. Hence, we also studied B-cell lymphomas that can be
associated with SS [22]. We observed a similar paucity of
APRIL-producing cells and absence of secreted APRIL in
these tumour cases (data not shown). Taken together,
these show that APRIL expression is weak in autoimmune
and tumoural SS.
APRIL expression in minor salivary glands from
patients with SS harbouring PC accumulation
As discussed above, the primary role of APRIL is to sus-
tain PC survival. PCs frequently accumulate in minor sal-
ivary glands from SS patients [23], and ectopic germinal
centres (GCs) have also been described in some SS le-
sions [24]. Hence, APRIL might be more predominant in
these cases. We studied six SS cases with accumulating
PCs (496 ± 319, ranging from 209 to 926/4 mm2), and one
of these cases even showed an ectopic GC. In such a
case, PCs localized outside the GC in the interstitial
space among salivary glands (Fig. 2). At that site, we de-
tected neither APRIL-producing cells nor secreted APRIL.
This shows that PCs accumulate in SS salivary glands in
areas devoid of detectable APRIL.
APRIL expression in normal salivary glands
We next studied healthy salivary glands. Notably, the ex-
pression of APRIL was very similar, at the level of the
production and concentration of secreted APRIL. Cells
from the upper layers of the oral epithelium also produced
APRIL (Fig. 3A, upper panel), to a level comparable with
SS lesions as assessed by a quantitative analysis of the
Stalk-1 staining (Fig. 3A, bottom panel). Interstitial APRIL-
producing neutrophils were barely detectable, and se-
creted APRIL was again virtually absent from this tissue
(data not shown). Quantitative comparative study be-
tween pathological (autoimmune and tumoural) and
healthy tissues indicated that the number of APRIL-
producing cells was only slightly increased in 5/14 auto-
immune SS lesions, but the entire SS cohort did not show
any statistically significant up-regulation compared with
healthy salivary glands (Fig. 3B). The values obtained
here for APRIL-producing cells infiltrating SS lesions were
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10-fold less than the one we previously observed in RA
synovium [12]. To further compare these two rheumatic
diseases, we also studied salivary glands from secondary
SS subsequent to RA. These lesions were as low as pri-
mary SS lesions for APRIL-producing cells, and were also
devoid of secreted APRIL (data not shown). Taken to-
gether, this demonstrates the absence of APRIL
up-regulation in salivary glands from SS despite high
infiltration.
Discussion
The present study demonstrates that APRIL production
in SS lesions was low. We observed this with
FIG. 1 Oral epithelium produces APRIL, but no retention of secreted APRIL in salivary glands from SS lesions. (A) Serial
sections of salivary glands from SS patients were immunostained with control Ig (cIg), Stalk-1 and Aprily-8 (Ap-8).
Pictures are representative of 14 primary SS lesions. (B) High magnification (63) of a Stalk-1-stained cell in the par-
enchyma of a salivary gland from SS (left panel). APRIL-producing cells (Stalk-1 staining, green) express elastase
(red staining) (right panel). Single and merged pictures from two-colour IF are representative of four SS lesions. (C) Serial
sections of the adjacent oral epithelium from SS lesions were immunostained as in (A). Pictures are representatives of five
biopsies from SS lesions with epithelium presence.
FIG. 2 Absence of APRIL expression in SS lesions infiltrated by PCs. Serial sections of an SS lesion with GC formation
and PC generation were immunostained with an anti-CD138, Stalk-1 and Ap-8. GC light zone (). Representative clusters
of CD138+ cells (#). Insert represents a 100 magnification of a CD138+ cell.
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primary SS, secondary SS subsequent to RA and B-cell
lymphoma associated with SS. This is in marked contrast
with the high APRIL production that can be observed
in RA and B-cell lymphoma lesions. Furthermore,
pathological salivary glands did not retain secreted
APRIL, as opposed to RA. In fact, levels of APRIL expres-
sion in SS lesions were very similar to corresponding
healthy tissues. The absence of APRIL up-regulation
observed here is consistent with the predominant pres-
ence of lymphoid cells in SS infiltrates [25], over myeloid
cells, the latter constituting the most important source
of APRIL in tissues [19]. Our present results imply that
the elevated level of APRIL reported in patients’ sera
is unlikely to originate from lesions, but rather from other
sites of APRIL production. Since precursor and mature
granulocytes are both producing APRIL in the bone
marrow and blood, respectively [12, 18], our results
indicate that an increased myelopoiesis, already reported
for other rheumatic diseases such as SLE [26], may ex-
plain up-regulation of circulating APRIL in SS patients.
Taken together, the present report indicates that PCs pre-
sent in SS may not be dependent on APRIL for survival in
lesions. To our knowledge, this is the first in situ demon-
stration of PCs residing in a tissue devoid of APRIL. Such
an observation warrants further investigations with the
study of more SS lesions with ectopic GCs, as well
as SS lesions developing at other mucosa-associated
lymphoid tissue (MALT) sites, due to the APRIL key role
for PCs in healthy MALTs [9]. It should also be noted
that our present report does not reccomend not using
APRIL targeting reagents for the treatment of SS; rather
it indicates that these approaches will primarily affect
bone marrow-homed PCs secreting autoantibodies
systemically.
FIG. 3 Quantification of APRIL production in pathological and healthy salivary glands. (A) Healthy salivary glands
were immunostained with cIg and Stalk-1. The adjacent epithelium is shown (upper panel). Intensity of the Stalk-1
staining in the indicated epithelium was quantified and reported in arbitrary units (a.u.) (lower panel). (B) The number of
Stalk-1-stained cells is shown for healthy salivary glands (n= 4), primary SS salivary glands (n= 14), B-cell lymphoma
associated with SS (n= 5) and secondary SS salivary glands following RA (n= 4). SS lesions infiltrated by PCs (*). NS: not
significant.
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Rheumatology key messages
. Salivary glands from SS do not harbour APRIL
up-regulation.
. Plasma cells infiltrating salivary glands from SS do
not rely on APRIL for survival.
. APRIL antagonism in SS may still be valuable by
targeting lymphoid organ-resident plasma cells.
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